Large gap with delayed quotes
|
Last quote
05/29/2026
-
17:31:09
|
Bid
05/29/2026 -
21:53:22
|
Bid Volume |
Ask
05/29/2026 -
17:40:00
|
Ask Volume |
|---|---|---|---|---|
|
13.62
-0.94
(
-6.46% )
|
13.98
|
47 |
13.98
|
100 |
Analysis date: 29.05.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 24.04.2026.
Interest
None
None
No stars since 28.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend active since more than one year
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 24.04.2026.
4wk Rel Perf
-12.88%
-12.88%
The four-week dividend-adjusted underperformance versus STOXX600 is 12.88%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.29%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.54%.
Mkt Cap in $bn
0.36
0.36
With a market capitalization <$2bn, NEWRON PHARMACEUTICALS SPA is considered a small-cap stock.
G/PE Ratio
-0.91
-0.91
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-18.59
-18.59
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-16.97%
-16.97%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
65
65
For 1% of index variation, the stock varies on average by 0.65%.
Correlation
0.13
0.13
Stock movements are totally independent of index variations.
Value at Risk
5.31
5.31
The value at risk is estimated at CHF 5.31. The risk is therefore 38.98%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
24.04.2018
24.04.2018